- Home
- IKNA vs SAVA Comparison
IKNA vs SAVA Comparison
Compare IKNA & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKNA
- SAVA
- Stock Information
- Founded
- IKNA 2016
- SAVA 1998
- Country
- IKNA United States
- SAVA United States
- Employees
- IKNA N/A
- SAVA N/A
- Industry
- IKNA Biotechnology: Pharmaceutical Preparations
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- IKNA Health Care
- SAVA Health Care
- Exchange
- IKNA Nasdaq
- SAVA Nasdaq
- Market Cap
- IKNA 61.8M
- SAVA 70.5M
- IPO Year
- IKNA 2021
- SAVA N/A
- Fundamental
- Price
- IKNA $1.36
- SAVA $2.01
- Analyst Decision
- IKNA Strong Buy
- SAVA Buy
- Analyst Count
- IKNA 1
- SAVA 3
- Target Price
- IKNA $4.00
- SAVA $54.50
- AVG Volume (30 Days)
- IKNA 95.6K
- SAVA 857.6K
- Earning Date
- IKNA 08-07-2025
- SAVA 08-07-2025
- Dividend Yield
- IKNA N/A
- SAVA N/A
- EPS Growth
- IKNA N/A
- SAVA N/A
- EPS
- IKNA N/A
- SAVA N/A
- Revenue
- IKNA N/A
- SAVA N/A
- Revenue This Year
- IKNA N/A
- SAVA N/A
- Revenue Next Year
- IKNA N/A
- SAVA N/A
- P/E Ratio
- IKNA N/A
- SAVA N/A
- Revenue Growth
- IKNA N/A
- SAVA N/A
- 52 Week Low
- IKNA $0.97
- SAVA $1.15
- 52 Week High
- IKNA $1.94
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- IKNA 56.43
- SAVA 51.81
- Support Level
- IKNA $1.10
- SAVA $2.01
- Resistance Level
- IKNA $1.46
- SAVA $2.17
- Average True Range (ATR)
- IKNA 0.07
- SAVA 0.10
- MACD
- IKNA -0.00
- SAVA -0.02
- Stochastic Oscillator
- IKNA 57.58
- SAVA 17.31
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.